Genetically engineered microbes and methods for producing citramalate
View Patent ↗Provided herein is a genetically engineered microbe which accumulates citramalate. In one embodiment, the microbe includes an exogenous polynucleotide encoding a citramalate synthase which catalyzes the condensation of acetyl CoA and pyruvic acid. Optionally, the microbe also includes a second exogenous polynucleotide encoding a citrate synthase which catalyzes the condensation of acetyl CoA and oxaloacetate, and the citrate synthase activity in the microbe is reduced compared to a control microbe. In one embodiment, the citrate synthase includes at least one amino acid substitution in the acetyl-CoA binding pocket, the mobile loop, the NADH binding site, and the oxaloacetate binding site, or a combination thereof. Also provided herein are methods for using the genetically engineered microbe, including a method for producing citramalate. The method can further include isolating the citramalate.
1. A genetically engineered microbe which accumulates citramalate,
wherein the microbe comprises a first exogenous polynucleotide encoding a citramalate synthase which catalyzes the condensation of acetyl CoA and pyruvic acid, and
wherein the microbe comprises a second exogenous polynucleotide encoding a citrate synthase which catalyzes the condensation of acetyl CoA and oxaloacetate, and the citrate synthase activity in the microbe is reduced compared to a control microbe.
2. The genetically engineered microbe of claim 1 wherein the second exogenous polynucleotide is present in the chromosome.
3. The genetically engineered microbe of claim 1 wherein the citrate synthase encoded by the second exogenous polynucleotide comprises at least one amino acid substitution, wherein the at least one amino acid substitution is associated with the reduced citrate synthase activity, and wherein the at least one amino acid substitution is an amino acid associated with the acetyl-CoA binding pocket, the mobile loop, the NADH binding site, the oxaloacetate binding site, or a combination thereof.
4. The genetically engineered microbe of claim 1 wherein the citrate synthase encoded by the second exogenous polynucleotide comprises at least one amino acid substitution, wherein the at least one amino acid substitution is associated with the reduced citrate synthase activity, and wherein the at least one amino acid substitution is at a position functionally equivalent to F383, D362, R407, H229, R314, R387, A123, A257, A258, A161, or a combination thereof, of SEQ ID NO:5.
5. The genetically engineered microbe of claim 4
wherein the substitution of the amino acid at a position functionally equivalent to F383 is F383I, F383M, F383L, F383V, F383A, F383Y, or F383K,
wherein the substitution of the amino acid at a position functionally equivalent to D362 is D362V, D362I, or D362E,
wherein the substitution of the amino acid at a position functionally equivalent to A123 is A123 T,
wherein the substitution of the amino acid at a position functionally equivalent to A257 is A257T,
wherein the substitution of the amino acid at a position functionally equivalent to A258 is A258T,
wherein the substitution of the amino acid at a position functionally equivalent to A161 is A161V, or a combination thereof.
6. The genetically engineered microbe of claim 1 wherein the microbe is E. coli.
7. The genetically engineered microbe of claim 1 wherein the citrate synthase catalyzes the condensation of acetyl CoA and oxaloacetate at a rate that is less than the rate of condensation by the wild type citrate synthase naturally present in the microbe.
8. The genetically engineered microbe of claim 1 wherein the microbe produces at least 2.5 g/L citramalate in 30 hours based on batch culture conditions.
9. The genetically engineered microbe of claim 1 wherein the microbe produces at least 35 g/L in 132 hours based on fed-batch culture conditions.
10. The genetically engineered microbe of claim 9 wherein the carbon source is glucose, and the citramalate yield is at least 0.4 g/g.
11. The genetically engineered microbe of claim 1 wherein the microbe further comprises reduced expression of a coding region encoding a protein that converts pyruvate to acetate compared to the control microbe.
12. The genetically engineered microbe of claim 11 wherein the microbe further comprises reduced expression of a coding region encoding a protein that converts acetate-phosphate to acetate compared to the control microbe.
13. The genetically engineered microbe of claim 1 wherein the microbe further comprises reduced expression of a coding region encoding a protein that converts acetyl CoA to acetate-phosphate compared to the control microbe.
14. A method for producing citramalate comprising:
culturing the microbe of claim 1 under suitable conditions resulting in the production of citramalate.
15. The genetically engineered microbe of claim 1 wherein the microbe expresses a reduced amount of a citrate synthase protein compared to the control microbe.
16. The genetically engineered microbe of claim 11 wherein the coding region encoding the protein that converts pyruvate to acetate is a pyruvate oxidase.
17. The genetically engineered microbe of claim 12 wherein the coding region encoding the protein that converts acetate-phosphate to acetate is an acetate kinase.
18. The genetically engineered microbe of claim 13 wherein the coding region encoding the protein that converts acetyl CoA to acetate-phosphate is a phosphotransacetylase.
19. The method of claim 14 wherein the suitable conditions comprise use of glucose, glycerol, or a combination thereof, as a carbon source.
20. The method of claim 14 further comprising chemically synthesizing methacrylic acid from the citramalate.